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Although discovered in 1974, FGF1 was previously unrealized to have a role in metabolism. Suh et al. (2014)
now report impressive pharmacological outcomes of FGF1 therapy inmice that imply this protein is an impor-
tant metabolic regulator with therapeutic potential in the treatment of insulin resistance and type 2 diabetes.The breakthrough discovery of FGF1 in
the early 1970s and the advances in
gene cloning that followed paved the
way to an expansion of the FGF family,
which today consists of 22 human ortho-
logs. Subsequent identification of the cor-
responding receptors (FGFRs) revealed
the existence of four distinct functional
FGFR tyrosine kinases. These receptors
are widely expressed endogenously and
appear in multiply altered forms, due to
tissue-specific alternative splicing (Been-
ken and Mohammadi, 2009). FGF1 and
related isoforms are well established as
proliferative agents, and as such the pre-
vailing direction in FGF research was
focused on biological process associated
with transformation, mitosis, and cellular
development. Nonetheless, a collec-
tion of biochemical reports began to
emerge early last decade that suggested
potential links of FGFs to metabolic
homeostasis.
The role of FGF1 in adaptive adipose
remodeling was recently reported where
imposition of a high-fat diet tomice devoid
of FGF1 led to an aggressive diabetic
phenotype, suggesting a physiologic role
for this factor in managing a metabolic
challenge (Jonker et al., 2012). These
genetic-based studies were followed
by pharmacology experiments employing
biosynthetic FGF1 and now communi-
cated in the recent report from Suh et al.
(2014). The administration of FGF1 to a va-
riety of mice with impaired insulin sensi-
tivity led to impressive changes in several
measures of metabolism. Blood glucose
was nearly normalized following a single
injection of FGF1, and there was no sign
of hypoglycemia at any dose tested. Of
note, these effects were achieved at phar-
macologically relevant FGF1 doses (low
nM/kg) and were long-lasting as the ani-
mals remained sensitive to FGF1 treat-554 Cell Metabolism 20, October 7, 2014 ª20ment through 35 days of administration.
In this setting, Suh et al. (2014) observed
an increase in skeletal muscle insulin-
dependent glucose uptake and the sup-
pression of hepatic glucose production,
reflecting the presumed underlying mech-
anism for improvement in glycemic con-
trol. Importantly, no adverse effects such
as weight gain, liver steatosis, or bone
loss that are commonly associatedwith in-
sulin sensitizing TZD-based therapies
were seen with FGF1 treatment.
FGF1 can bind and signal via any FGFR
variant, and yet the in vitro and in vivo ex-
periments reported by Suh et al. (2014)
attribute themajority of the pharmacology
to adipose tissue-specific FGFR1 as
the key receptor underlying FGF1 meta-
bolic activities. This FGF1 pharmacolog-
ical profile is highly reminiscent of the
glucose-lowering effects achieved in
rodents through therapy with another
member of the FGF superfamily, FGF21
(Kharitonenkov et al., 2005). FGF21 re-
quires the transmembrane cofactor KLB
for its receptor activation, but its meta-
bolic signal is propagated via engage-
ment of the same FGFR1 (Adams et al.,
2012). The integrity of fat-specific
FGFR1/KLB complex is critical for
FGF21 pharmacology in animals (Ding
et al., 2012). Indeed, enzymatically
competent FGF receptors are the molec-
ular mediators that propagate ligand-
triggered intracellular signaling. Conse-
quently, any molecule of non-FGF nature
that activates FGFR1 in an analogous
fashion to FGF1 and FGF21 can poten-
tially elicit the full spectrum of metabolic
effects (Zhang and Li, 2014).
As opposed to FGF21 (Wei et al., 2012),
the finding that FGF1 did not induce detri-
mental changes in mouse bone quality is
encouraging. However, FGF1 did not pro-
mote body weight loss or plasma lipid14 Elsevier Inc.lowering, as seen with FGF21 therapy.
Since the effects of FGF21 on glucose
and lipid levels are believed to derive
differentially at adipose and liver (Adams
et al., 2012) it seems plausible that FGF1
is more restricted in its action, possibly a
result of its sequestration from circulation
by heparan-sulfate proteoglycans in adi-
pose tissue. Can an FGF1 variant devoid
of heparin binding be of enhanced func-
tion and demonstrate the fuller spectrum
of activity associated with multifaceted
FGF21?
Given the mitogenic properties of
FGF1, it is highly unlikely that FGF1 would
be used in its native form for the treatment
of chronic diseases such as diabetes.
Although overproliferation with FGF1
was not established in this report, Suh
et al. (2014) re-engineered the native pro-
tein to mitigate its inherent mitogenic ac-
tivity. They eloquently demonstrated that
the N-terminally truncated FGF1 mutant,
FGF1DNT, is more discrete in its FGFR
binding profile. This FGF1 analog showed
a slightly reduced affinity at FGFR1, with
sizable reduction at FGFR2 and no
apparent activity at FGFR3 and FGFR4.
Such dramatic enhancement in receptor
selectivity is the likely basis for the sig-
nificantly lowered mitogenic character of
FGF1DNT when studied in NIH 3T3 fib-
roblasts. This FGF1 variant could serve
as an initial scaffold for further structural
optimization to support drug develop-
ment. A central question that remains is
whether the reduced cell-based mito-
genicity of FGF1DNT will translate in vivo
through additional animal models and
more extended study. Furthermore, a
thorough assessment of the relative risk-
benefit in comparison to FGF21-based
candidates seems warranted.
A curious observation worthy of addi-
tional consideration is the fact that FGF2,
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Previewsamong the broader set of FGFs tested (1,
2, 9, and 10), did not demonstrate in vivo
glycemic efficacy in Suh et al. (2014).
FGF2 is almost as promiscuous as FGF1
in binding several FGFR isoforms and is
identical in its in vitro potency at the
FGFR1 when compared to FGF1 (Ornitz
et al., 1996). Consequently, in view of the
purported mechanism of FGF1 action
in vivo, it is unexpected that FGF2 would
not show a comparable level of efficacy.
Further pursuit of this paradox might
shed light on the purported mechanism
of FGF1 action and assist in designing
optimal clinical candidates.
Sowe have come full circle through four
decades of FGF research to a point where
we now have experimental evidence
validating the physiological role of FGF1
in metabolism to complement its more
established role as an anabolic agent.
The observation that FGF1 improves gly-
cemia without lipid, weight, or bone loss
is curious and distinguishes it from
FGF21 pharmacology. From a transla-tional perspective, Suh et al. provide initial
direction in optimization of native FGF1
for potential therapeutic use. Subsequent
refinement will surely benchmark against
FGF21, which has provided evidence of
clinical efficacy consistent with preclinical
observations, yet failed to offer a robust
glucose-lowering effect (Kharitonenkov
and Adams, 2014). It has taken four de-
cades to discover the metabolic activity
of FGF1, which, in a broader context, illus-
trates the commitment necessary to
biologically validate novel proteins. This
newly observed function provides a rea-
son to believe that breakthrough therapy
in adult-onset diabetes may be within
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Reinduction of fetal gene expression is characteristic of the failing adult heart. Han et al. (2014) demonstrate
that a novel cluster of long noncoding RNAs, Myheart, protects the heart from pathological hypertrophy,
involving a negative-feedback molecular circuit with the epigenetic Brg1 complex to inhibit fetal-gene
reactivation.Human hearts are capable of undergo-
ing remarkable cardiac remodeling in
response to various environmental stim-
uli. Cardiac hypertrophy is one of the
primary responses of the heart to patho-
physiological stress. While physiological
hypertrophy enhances cardiac perfor-
mance to match physiological demands,
pathological hypertrophy results in a
decrease in cardiac function, accompa-
nied by reinduction of the fetal gene pro-
gram and increased fibrosis, representinga maladaptive response to pathological
stress/stimuli, which often progresses to
heart failure if prolonged (Ahmad et al.,
2005; Hill and Olson, 2008). Two myosin
heavy-chain genes, Myh6 and Myh7,
which encode the a- and b-MHC contrac-
tile proteins, respectively, are expressed
in mammalian hearts in opposing pat-
terns during cardiac development and
remodeling. Cardiac injury shifts this
ratio toward Myh7, with detrimental ef-
fects on cardiac functions and outcomes.Transcriptional and epigenetic regulation
govern the expression of Myh6 and
Myh7 genes (Hill and Olson, 2008), and
genetic mutations and altered expression
of these genes have been linked to car-
diac hypertrophy and other cardiomyopa-
thies (Ahmad et al., 2005). More recently,
miR-208a and miR-208b, encoded by in-
trons of Myh6 and Myh7, respectively,
have also been involved in the regulation
of a/b-MHC expression in pathological
cardiac hypertrophy (Callis et al., 2009;0, October 7, 2014 ª2014 Elsevier Inc. 555
